In the past few years much effort in our laboratory has been directed toward the study of adenosine receptor antagonists, and recently we focused our attention on 2-aryl-1,2,4-triazolo- [4,3-a]quinoxaline-1,4-diones and 2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-4-amino-1-ones, some of which were potent and/or selective A3 receptor antagonists. In the present paper, a new series of triazoloquinoxaline derivatives is described. Most of the new compounds, biologically evaluated in radioligand binding assays at bovine (b) A1 and A2A and at human (h) A1 and A3 adenosine receptors, showed high hA3 adenosine receptor affinity and selectivity. In particular, 2-(4-nitrophenyl)-1,2,4,5-tetrahydro-1,2,4-triazolo[4,3-a]quinoxaline-1,4-dione (1), also tested at the hA2A ARs, shows the best binding profile with a high hA3 affinity (Ki ) 0.60 nM) and strong selectivity vs hA1 and vs hA2A receptors (both selectivity ratios greater than 16 600). To interpret our experimental results, we decided to theoretically depict the putative transmembrane binding motif of our triazoloquinoxaline analogues on hA3 receptor. Structure-activity relationships have been explained analyzing the three-dimensional structure of the antagonistreceptor models obtained by molecular docking simulation.

The 1,2,4-Triazolo[4,3-a]quinoxalin-1-one Moiety as an Attractive Scaffold to Develop New Potent and Selective Human A3 Adenosine Receptor Antagonists: Synthesis, Pharmacological and Ligand-Receptor Modeling Studies / V. COLOTTA; D. CATARZI; F.VARANO; F. R. CALABRI; O. LENZI; G. FILACCHIONI; C. MARTINI; L. TRINCAVELLI; FRANCESCA DEFLORIAN; STEFANO MORO. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - STAMPA. - 47(2004), pp. 3580-3590.

The 1,2,4-Triazolo[4,3-a]quinoxalin-1-one Moiety as an Attractive Scaffold to Develop New Potent and Selective Human A3 Adenosine Receptor Antagonists: Synthesis, Pharmacological and Ligand-Receptor Modeling Studies.

COLOTTA, VITTORIA;CATARZI, DANIELA;VARANO, FLAVIA;FILACCHIONI, GUIDO;
2004

Abstract

In the past few years much effort in our laboratory has been directed toward the study of adenosine receptor antagonists, and recently we focused our attention on 2-aryl-1,2,4-triazolo- [4,3-a]quinoxaline-1,4-diones and 2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-4-amino-1-ones, some of which were potent and/or selective A3 receptor antagonists. In the present paper, a new series of triazoloquinoxaline derivatives is described. Most of the new compounds, biologically evaluated in radioligand binding assays at bovine (b) A1 and A2A and at human (h) A1 and A3 adenosine receptors, showed high hA3 adenosine receptor affinity and selectivity. In particular, 2-(4-nitrophenyl)-1,2,4,5-tetrahydro-1,2,4-triazolo[4,3-a]quinoxaline-1,4-dione (1), also tested at the hA2A ARs, shows the best binding profile with a high hA3 affinity (Ki ) 0.60 nM) and strong selectivity vs hA1 and vs hA2A receptors (both selectivity ratios greater than 16 600). To interpret our experimental results, we decided to theoretically depict the putative transmembrane binding motif of our triazoloquinoxaline analogues on hA3 receptor. Structure-activity relationships have been explained analyzing the three-dimensional structure of the antagonistreceptor models obtained by molecular docking simulation.
47
3580
3590
V. COLOTTA; D. CATARZI; F.VARANO; F. R. CALABRI; O. LENZI; G. FILACCHIONI; C. MARTINI; L. TRINCAVELLI; FRANCESCA DEFLORIAN; STEFANO MORO
File in questo prodotto:
File Dimensione Formato  
colottajmc_04_47_3580.pdf

Accesso chiuso

Tipologia: Altro
Licenza: DRM non definito
Dimensione 293.69 kB
Formato Adobe PDF
293.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2158/311062
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 73
  • ???jsp.display-item.citation.isi??? 66
social impact